Table 5.

Cox regression analysis for predictive value of inflammatory indexes in prognosis of stage IIB cervical cancer.

Prognosis	Inflammatory indexes		N	Mean ± SE (month)	HR (95% CI)	P value	HR (95% CI)	P value
OS	PLR
		<154.17	129	76.47 ± 3.14	1 (reference)		1 (reference)
		≥154.17	131	74.64 ± 3.21	1.049 (0.667–1.649)	0.837	1.044 (0.662–1.645)	0.854
	NLR
		<2.49	130	82.27 ± 2.81	1 (reference)		1 (reference)
		≥2.49	130	69.02 ± 3.40	1.960 (1.227–3.131)	0.005	1.721 (1.068–2.773)	0.026
	MLR
		<0.26	131	82.55 ± 2.76	1 (reference)		1 (reference)
		≥0.26	129	69.17 ± 3.49	2.012 (1.258–3.217)	0.003	1.780 (1.099–2.881)	0.019
	BLR
		<0.021	129	75.26 ± 3.25	1 (reference)		1 (reference)
		≥0.021	131	75.77 ± 3.12	0.948 (0.603–1.492)	0.818	0.902 (0.573–1.419)	0.654
	SIRI
		<1.02	130	79.56 ± 2.93	1 (reference)		1 (reference)
		≥1.02	130	72.46 ± 3.38	1.446 (0.916–2.283)	0.113	1.271 (0.796–2.028)	0.315
PFS	PLR
		<154.17	129	70.48 ± 3.44	1 (reference)		1 (reference)
		≥154.17	131	68.48 ± 3.48	1.082 (0.719–1.629)	0.706	1.004 (0.665–1.514)	0.986
	NLR
		<2.49	130	77.22 ± 3.15	1 (reference)		1 (reference)
		≥2.49	130	62.18 ± 3.58	1.944 (1.274–2.967)	0.002	1.736 (1.129–2.669)	0.012
	MLR
		<0.26	131	77.35 ± 3.14	1 (reference)		1 (reference)
		≥0.26	129	62.33 ± 3.65	1.992 (1.303–3.043)	0.001	1.806 (1.169–2.791)	0.008
	BLR
		<0.021	129	68.89 ± 3.51	1 (reference)		1 (reference)
		≥0.021	131	70.37 ± 3.36	0.941 (0.625–1.417)	0.769	0.888 (0.589–1.338)	0.570
	SIRI
		<1.02	130	74.76 ± 3.26	1 (reference)		1 (reference)
		≥1.02	130	64.12 ± 3.81	1.538 (1.015–2.329)	0.042	1.379 (0.901–2.110)	0.139

PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; SIRI, systemic inflammation response index; OS, overall survival. PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.